Cystic Fibrosis Foundation Therapeutics Inc. will award up to $1.7 million to Alaxia SAS to test the safety of a potential inhaled therapy that may fight drug-resistant bacteria that infect people with cystic fibrosis
Site Search
Cystic Fibrosis Foundation Therapeutics Inc. has awarded more than $4 million to AlgiPharma AS to continue Phase 2 clinical trials for a drug that may help restore normal function to cystic fibrosis mucus and make it easier for people with CF to cough out.
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will provide up to $3 million through a drug development award to Swiss pharmaceutical company Polyphor Ltd. to continue clinical trials of a potential anti-inflammatory drug. The drug, POL6014, inhibits the activity of an enzyme that can destroy lung tissue if produced in excess.
The lab will use the latest scientific advances -- including stem cell research and gene editing -- to accelerate new treatments for cystic fibrosis.
The U.S. Food and Drug Administration has approved a device, called RELiZORB®, that helps break down beneficial fats in supplemental nutrition provided via G-tubes.
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $5 million development award to Corbus Pharmaceuticals for a potential new therapy to reduce lung inflammation in people with CF.
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
The U.S. Food and Drug Administration approved an important new inhaled
The U.S. Food and Drug Administration (